Copyright
©The Author(s) 2021.
World J Clin Cases. Apr 6, 2021; 9(10): 2160-2169
Published online Apr 6, 2021. doi: 10.12998/wjcc.v9.i10.2160
Published online Apr 6, 2021. doi: 10.12998/wjcc.v9.i10.2160
Microorganisms | Antimicrobial drugs | Treatment duration (for all regimens) |
Gram-negative bacilli and multidrug-resistant pathogens | Meropenem or imipenem-cilastatin or piperacillin-tazobactam or doripenem; Anaerobic microorganisms: Ceftazidime or cefepime associated with metronidazole; New schemes: Ceftolozana or ceftazidime + tazobactam or avibactam; Fluorocyclines | Patients with controlled infectious focus: No more than 96 h. Patients who not yet undergone definitive control of the infectious focus: 5-7 d |
Enterococcus spp | Include ampicillin or vancomycin | |
MRSA | Include vancomycin | |
Candida spp | Critical patients: Echinocandins; Patients in clinical remission: Azoles |
- Citation: Marques HS, Araújo GRL, da Silva FAF, de Brito BB, Versiani PVD, Caires JS, Milet TC, de Melo FF. Tertiary peritonitis: A disease that should not be ignored. World J Clin Cases 2021; 9(10): 2160-2169
- URL: https://www.wjgnet.com/2307-8960/full/v9/i10/2160.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i10.2160